Viyash Scientific Q3 FY26 Earnings Call Transcript Released
Viyash Scientific reported Q3 FY26 revenue of ₹858 crore, up 11% YoY, with Adjusted EBITDA at ₹185 crore, up 64% and margins at 21%. For 9M FY26, revenue reached ₹2,500 crore (up 12%) and EBITDA was over ₹500 crore (up 58%). The company is confident in sustaining 20% EBITDA margins and achieving FY27 targets earlier than planned.
The announcement is a transcript of an earnings call, providing detailed financial performance and future outlook. While positive, it does not introduce entirely new material events but elaborates on existing financial results and strategies.
The company reported strong year-on-year growth in revenue and significant improvement in profitability and EBITDA margins. The reduction in net debt and confidence in sustaining margins further contribute to a positive sentiment.
Viyash Scientific Limited (formerly Sequent Scientific Limited) has released the transcript of its earnings conference call for the quarter and nine months ended December 31, 2025. The call, held on February 06, 2026, featured insights from Dr. Hari Babu (Managing Director & Group CEO), Mr. Rajaram Narayanan (Executive Director & CEO - Animal Health), and Mr. Ramakant Singani (CFO).
Dr. Hari Babu highlighted that Q3 FY'26 saw revenue from operations grow by 11% year-on-year to ₹858 crore, with Adjusted EBITDA increasing by 64% to ₹185 crore, resulting in an EBITDA margin of 21% (a 390 basis points expansion). Net debt-to-EBITDA reduced to less than 4x. For the nine-month period, revenue grew 12% to ₹2,500 crore and Adjusted EBITDA increased by 58% to over ₹500 crore, maintaining margins above 20%. The company incurred one-time exceptional items related to merger execution totaling approximately ₹48-49 crore.
The company is focusing on growth in companion animals, leveraging its integrated platform, and expanding its API and CDMO businesses. Future strategies include organic and inorganic growth, with a strong emphasis on companion animal health, particularly in India, through a distribution agreement with Boehringer Ingelheim. The company also aims to compound momentum by focusing on companion animals and expanding its farm animal business in emerging markets.
The CFO, Mr. Ramakant Singani, provided detailed financial figures, stating that total revenue for Q3 FY'26 reached ₹8.5 billion (₹850 crore), with formulations revenue growing 20% to ₹4.8 billion and API revenue rising 2.9% to ₹3.6 billion. Gross margins improved to 54.5%, and Adjusted EBITDA surged 64.4% to ₹1.8 billion (₹180 crore), with margins expanding to 21.6%. Profit before tax was ₹731 million after accounting for ₹413 million in one-time merger expenses. Profit after tax was ₹485 million, also after accounting for a one-time charge of ₹77 million on MAT credit reversal.
For the 9-month period, total revenue increased by 11.9% to ₹25 billion, Adjusted EBITDA jumped 58% to ₹5 billion, with margins up to 20.1%. The company expressed confidence in sustaining the 20% EBITDA margin and achieving future growth targets, including ₹4,000 crore revenue and 20% EBITDA by FY'27, earlier than previously projected for FY'28.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.